v3.26.1
Significant agreements - Genentech Collaboration Agreement (Details)
$ in Thousands
1 Months Ended 12 Months Ended
Feb. 21, 2020
USD ($)
item
Jan. 31, 2025
USD ($)
Jun. 30, 2022
USD ($)
Oct. 31, 2021
USD ($)
Dec. 31, 2025
USD ($)
item
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Significant agreements.                  
Collaboration revenue         $ 72,586 $ 35,275 $ 26,976    
Deferred revenue         38,469 101,658 135,194    
Genentech                  
Significant agreements.                  
Number of potential development candidates | item 4                
Collaboration revenue         14,681 14,840 11,969    
Deferred revenue         $ 0 14,038 29,104    
Number of immuno oncology targets | item 2                
Additional number of immuno oncology targets | item 2                
Expansion fee $ 10,000                
Transaction price 31,000               $ 33,000
Payment received 30,000                
Genentech | Specified Targeting Arm Material Right Arm Program One                  
Significant agreements.                  
Milestone payments, receivable $ 1,000                
Genentech | Two material rights associated with the LSR Go Option for Collaboration Programs One And Two                  
Significant agreements.                  
Number of collaboration programs | item         2        
Number of expansion option collaboration programs | item         2        
Genentech | Material rights associated with the LSR Go Option for Collaboration Program One                  
Significant agreements.                  
Revenue recognized         $ 6,500        
Deferred revenue             $ 6,000    
Genentech | Collaboration Program 3 Performance Obligation                  
Significant agreements.                  
Collaboration revenue           $ 10,400      
Expansion fee     $ 10,000 $ 10,000          
Milestone payments, receivable       $ 1,000       $ 2,000  
Genentech | Material rights                  
Significant agreements.                  
Revenue recognized   $ 7,500